MedTrace Logo

Systemic Inflammatory Biomarkers in Ovarian Cancer

NCT06629831 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2024-10-09

No results posted yet for this study

Summary

In cancer patients, prognostic markers are needed to improve the management and clinical course of both the cancer itself and surgery therefor. Elevated systemic inflammatory markers are associated with morbidity and mortality in most cancer types. In this study, the investigators aimed to determine the prognostic value of inflammatory markers such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) in patients undergoing cytoreductive surgery for ovarian cancer.

Conditions

Interventions

OTHER

group with complications

Complications in patients undergoing cytoreduction surgery for ovarian cancer

OTHER

group without complications

Complications in patients undergoing cytoreduction surgery for ovarian cancer

Sponsors & Collaborators

  • Bakirkoy Dr. Sadi Konuk Research and Training Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-12-01
Completion
2024-09-27

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06629831 on ClinicalTrials.gov